We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

In this article, we are going to take a look at where Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) stands against other biggest gainers of last week. Investors gobbled up shares of ...

Below is Validea's guru fundamental report for TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA). Of the 22 guru strategies we follow, TEVA rates highest using our Twin Momentum Investor model based ...

In this article, we are going to take a look at where Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) stands against the other stocks. The stock market finished the first trading day of the year ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in the form of a safety-related boxed warning. The label update ...

Learn more › You likely know Teva best for its extensive sandals, which it has been making since the mid-’80s. Now, the company has released its first truly winterized hiking boots ...

About Teva:Teva Pharmaceutical Industries Ltd. (NYSE and ... of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...

From 2009 - 2023, the Teva Pharmaceuticals Marc A. Coshko Memorial grant program supported several academic researchers ("Teva Scholars") in the fields of organic and medicinal chemistry. Applications ...

NYSE:TEVA opened at $22.42 on Thursday. Teva Pharmaceutical Industries Limited has a 52 week low of $10.34 and a 52 week high of $22.50. The company has a fifty day simple moving average of $17.97 ...